Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.55 |
| ▸ | TUBB | P07437 | 2/20 | 0.55 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.55 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.55 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.55 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.55 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.55 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.55 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.55 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.55 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.55 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.55 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.55 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.55 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5119726 | 0.93 | SMN1; SMN2 (0.59) | SMN1; SMN2HTTNPC1RAB9AMAPK1 | |
| SCHEMBL5124433 | 0.92 | SMN1; SMN2 (0.61) | SMN1; SMN2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL5115865 | 0.92 | SMN1; SMN2 (0.56) | SMN1; SMN2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL5130018 | 0.92 | SMN1; SMN2 (0.51) | SMN1; SMN2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL5116111 | 0.91 | SMN1; SMN2 (0.55) | SMN1; SMN2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL5130190 | 0.90 | SMN1; SMN2 (0.55) | SMN1; SMN2TUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL5115812 | 0.89 | ALDH1A1 (0.54) | SMN1; SMN2RAB9AALDH1A1MAPTS1PR2 | |
| SCHEMBL5126596 | 0.89 | SMN1; SMN2 (0.56) | SMN1; SMN2HTTNPC1RAB9AMAPK1 | |
| SCHEMBL5130429 | 0.89 | RAB9A (0.52) | SMN1; SMN2HTTRAB9AALDH1A1MAPT | |
| SCHEMBL5120022 | 0.89 | CYP1A2 (0.55) | SMN1; SMN2MAPK1ALDH1A1MAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1888596-B1 | SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2014-10-22 | — | — | EP | claimed |
| US-8772307-B2 | Substituted spiro compounds and their use for producing pain-relief medicaments | GRUENENTHAL GMBH (DE) | 2014-07-08 | — | — | US | claimed |
| US-20080269271-A1 | Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders | GRUENENTHAL GMBH (DE) | 2008-10-30 | — | — | US | claimed |
| US-20080269271-A1 | Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders | GRUENENTHAL GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269271-A1 | Analgesics; antidepressants; neurodegenerative diseases; antiepileptic agents; cognition activators; antitussive agents; incotinence; irritable bowel syndrome; stroke; vision defects; antiinflammatory agents; skin disorders; diarrhea; eating disorders | INA, SCN1A, SI | SMN1; SMN2 79/4885TUBB4A 1082/4885TUBB 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.